Semaglutide vs. Tirzepatide: Comparing Weight Loss, Blood Sugar, and Side Effects

Semaglutide and tirzepatide are two of the most studied medications in modern weight management. Both belong to the GLP-1 receptor agonist class, but they differ in their mechanisms, their clinical trial results, and the populations they may suit best. Understanding those differences can help you have a more informed conversation with your healthcare provider.

How Each Medication Works

Semaglutide is a selective GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics a naturally occurring gut hormone that signals fullness to the brain, slows gastric emptying, and helps regulate blood sugar by stimulating insulin release in a glucose-dependent manner.

Tirzepatide takes a dual-agonist approach. It activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP is another incretin hormone involved in insulin secretion and fat metabolism. By targeting both pathways simultaneously, tirzepatide produces a broader metabolic effect than a single-agonist medication.

Weight Loss: What the Trials Show

The STEP clinical trial program established semaglutide's efficacy for weight management. In the landmark STEP 1 trial, participants using semaglutide 2.4 mg once weekly achieved a mean body weight reduction of 14.9% over 68 weeks, compared to 2.4% in the placebo group. The STEP 5 trial extended follow-up to 104 weeks and found a sustained mean weight loss of 15.2%.

Tirzepatide's weight loss data comes primarily from the SURMOUNT trial program. In the first head-to-head comparison between the two medications — the SURMOUNT-5 trial — participants using tirzepatide at maximum tolerated doses (10 mg or 15 mg) lost a mean of 20.2% of body weight over 72 weeks, compared to 13.7% for those using semaglutide 2.4 mg. Secondary endpoints, including waist circumference reduction, also favored tirzepatide.

• Semaglutide (STEP 1): ~14.9% mean weight loss at 68 weeks
• Tirzepatide (SURMOUNT-5): ~20.2% mean weight loss at 72 weeks
• Both significantly outperformed placebo in their respective trials

Blood Sugar Control

Both medications improve glycemic control, making them relevant for people with type 2 diabetes as well as those managing weight without diabetes. In the SURPASS-2 trial, which compared tirzepatide directly to semaglutide in people with type 2 diabetes, tirzepatide produced greater reductions in HbA1c (a measure of long-term blood sugar control) across all doses tested.

Semaglutide, however, has a longer and more extensive cardiovascular evidence base. Landmark trials including SUSTAIN-6, PIONEER-6, and the SELECT trial have demonstrated meaningful reductions in major adverse cardiovascular events for people using semaglutide. Tirzepatide's cardiovascular data is still maturing, with the SURPASS-CVOT trial establishing non-inferiority rather than superiority for cardiovascular outcomes.

Side Effect Profiles

The side effect profiles of semaglutide and tirzepatide are broadly similar. Gastrointestinal effects — nausea, diarrhea, vomiting, and constipation — are the most commonly reported adverse events for both medications. These effects are typically most pronounced during the dose-escalation phase and tend to diminish over time.

In the SURMOUNT-5 head-to-head trial, treatment discontinuation due to adverse events was actually more frequent in the semaglutide group than in the tirzepatide group, though both rates were relatively low. Both medications carry a boxed warning regarding a potential risk of thyroid C-cell tumors observed in animal studies, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Which Medication Is Right for You?

The choice between semaglutide and tirzepatide is not one-size-fits-all. Tirzepatide's dual mechanism appears to produce greater average weight loss in clinical trials, while semaglutide has a more established cardiovascular outcomes record. Individual response to these medications also varies — some people respond exceptionally well to semaglutide, while others may find tirzepatide better tolerated or more effective for their specific metabolic profile.

Other practical factors — including insurance coverage, availability, injection frequency preferences, and any existing health conditions — also play a role in the decision. A qualified healthcare provider can review your full medical history and help determine which option aligns best with your health goals.